Description

Fast IgM/IgG antibody detection for COVID-19 serological screening

The BIOBASE COVID-19 Rapid Test uses colloidal-gold immunoassay technology to qualitatively detect IgM and IgG antibodies against SARS-CoV-2 in human blood samples. Engineered for rapid serological assessment, the test yields results within 10–15 minutes and provides valuable insight into recent or past exposure to the virus. Its simple workflow requires only a small blood sample, and the built-in control line ensures reliable test performance. Designed for hospitals, outpatient clinics, screening points, and epidemiological studies, this antibody rapid test supports rapid evaluation of immune response and complementary diagnostic strategies alongside molecular testing.

Key Features & Technical Highlights:
• Dual IgM/IgG antibody detection — supports identification of early and past infections
• 10–15 minute result time — accelerates serological screening workflows
• Simple blood-based procedure — requires minimal training and equipment
• Internal quality control line — ensures consistent and valid results
• Ideal for clinical, community, and field screening — enhances large-scale testing efficiency

Workflow & Clinical Use:
The test enhances COVID-19 surveillance by providing fast, easy-to-administer antibody screening, helping clinicians assess exposure history and immune response in various settings.